Saw Palmetto vs Pygeum for BPH — what the prostate trials actually show
Saw palmetto (Serenoa repens) and pygeum (Prunus africana bark extract) are the two most-trialled botanicals for benign prostatic hyperplasia symptoms. The honest read is sobering. Cochrane reviews of saw palmetto (the larger, better-controlled trials — notably STEP and CAMUS) failed to show meaningful benefit over placebo on the International Prostate Symptom Score (IPSS). Pygeum has older positive trials but few rigorous modern ones. Both are well-tolerated. Real treatment options that work — alpha-blockers, 5-alpha-reductase inhibitors, behavioural training, and surgery for severe cases — exist and should anchor the conversation with a urologist.
Quick verdict
| Goal | Better choice | Why |
|---|---|---|
| IPSS improvement > placebo | Neither reliably | STEP and CAMUS saw palmetto trials were null; rigorous pygeum trials are limited. |
| Nocturia frequency | Pygeum (modest) | Older meta-analysis (Wilt 1998) showed reductions in nighttime urination, but trial quality was mixed. |
| Adjunct in mild BPH while observing | Either, low harm | Both well-tolerated; reasonable trial in mild symptoms, but expect modest effect. |
| Severe BPH / acute urinary retention | Neither | Alpha-blockers (tamsulosin), 5-ARIs, or surgical evaluation are appropriate. |
| Prostate cancer prevention | Neither | No evidence either prevents prostate cancer; don't substitute for screening discussion. |
| Cost / availability | Saw palmetto | More widely available; pygeum is increasingly restricted due to wild-harvesting/CITES concerns. |
How they actually work
Saw palmetto — 5-alpha-reductase and anti-inflammatory claims
Saw palmetto berry extract (Serenoa repens) contains fatty acids and phytosterols. Proposed mechanisms include weak 5-alpha-reductase inhibition (the enzyme that converts testosterone to DHT, the more potent androgen driving prostate growth), modest anti-inflammatory activity, and possible alpha-adrenergic effects. The most-studied preparation is Permixon, a lipidosterolic extract. Trial doses are 160 mg BID or 320 mg/day. Early small trials suggested benefit; larger, better-controlled trials (STEP 2006, CAMUS 2011) were null at standard and higher doses.
Pygeum — phytosterol-rich bark extract
Pygeum is the bark of the African plum (Prunus africana). Active constituents include phytosterols (beta-sitosterol), pentacyclic triterpenes, and fatty alcohols. Proposed mechanisms include anti-inflammatory activity at the prostate, growth-factor modulation, and weak androgen-pathway effects. Older meta-analysis (Wilt 1998) of 18 trials reported modest improvements in IPSS, peak flow, and nocturia, but trial quality was variable and modern replications are limited.
Why the saw palmetto trials shifted
Earlier saw palmetto trials, particularly those using Permixon and conducted in Europe, suggested modest benefit. The 2006 STEP trial (Bent et al., NEJM) randomised 225 men with moderate-to-severe BPH to saw palmetto 160 mg BID or placebo for 1 year and found no difference in any outcome. CAMUS (Barry 2011, JAMA) randomised 369 men to escalating saw palmetto doses up to 960 mg/day and again found no difference. Cochrane (Tacklind 2012) concluded saw palmetto does not improve LUTS or peak flow vs placebo.
Where pygeum sits
Pygeum has older positive trials and a Cochrane review (Wilt 2002) that concluded "may be a useful treatment option" but called for larger rigorous trials that haven't been done in the modern era. CITES (international wildlife trade) listings have limited supply. Modern access is variable; quality control is also variable. Reasonable extracts are standardised to 14% phytosterols at 100 mg/day or 200 mg/day.
Stacking with beta-sitosterol and other phytosterols
Beta-sitosterol (the active phytosterol in pygeum and other plant extracts) has its own evidence base for BPH — multiple small RCTs showing modest IPSS improvements at 60–130 mg/day. It's the "active compound" rationale that has more standalone evidence than saw palmetto. Some formulations combine saw palmetto + pygeum + beta-sitosterol; if any combination is justified, it's the addition of beta-sitosterol.
Dose, form, and timing
Saw palmetto: 320 mg/day of lipidosterolic extract (often 160 mg BID), standardised to 85–95% fatty acids. Permixon is the most-trialled brand. Take with food. 12+ weeks before assessing.
Pygeum: 100–200 mg/day standardised to 14% phytosterols. 6–8 weeks for full effect. Source quality varies widely; choose a reputable certified-sourced product.
Safety
Saw palmetto: well-tolerated. Mild GI upset. Rare reports of gynecomastia, decreased libido, ED — all weak signals and not consistently associated. Mild antiplatelet effect (discontinue before surgery).
Pygeum: well-tolerated. Mild GI upset. Long-term safety data limited; trials have been 8–12 weeks. Pregnancy: not relevant (BPH is a male condition); women should not take it.
The bigger BPH picture
Behavioural changes that genuinely help: fluid restriction in the evening; avoiding caffeine and alcohol; double-voiding; treating constipation; weight loss in overweight men. Pharmaceutical first-line: tamsulosin (alpha-blocker) for symptomatic relief; finasteride or dutasteride (5-ARI) if prostate is enlarged on imaging (slower-acting but reduces gland size). Combination therapy for moderate-to-severe disease. Procedures (TURP, UroLift, Rezum, prostatic artery embolization, simple prostatectomy) for refractory or severe disease.
Who should pick each
Pick pygeum if: you have mild BPH symptoms, you want to trial a botanical with at least some positive trial data, you can source a quality standardised product, you accept modest effect and 8+ weeks to assess.
Pick saw palmetto if: you accept the largely-null modern trial evidence and want a low-harm botanical to try (perhaps for placebo and habit benefit), or you specifically prefer the Permixon preparation and tolerate its uncertain effect.
Pick neither and see a urologist if: you have nocturia >2x/night, weak/intermittent stream, post-void dribbling, urgency, or any blood in urine. These deserve clinical evaluation and likely pharmaceutical treatment rather than a supplement trial.
What we'd actually buy
For mild BPH symptoms (IPSS 0–7) in someone who wants a botanical trial: beta-sitosterol 60 mg BID (cleaner active-compound evidence than either saw palmetto or pygeum extract), 8–12 weeks. For mild-to-moderate BPH with sleep-disrupting nocturia: see urology; alpha-blocker plus behavioural changes will outperform any botanical trial.
Sources
- Bent S, et al. Saw palmetto for benign prostatic hyperplasia (STEP). N Engl J Med. 2006;354(6):557–566. PMID: 16467543
- Barry MJ, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial (CAMUS). JAMA. 2011;306(12):1344–1351. PMID: 21954478
- Tacklind J, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;(12):CD001423. PMID: 23235581
- Wilt T, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044. PMID: 11869585
- Wilt TJ, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001043. PMID: 10796740
- Andriole GL, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with benign prostatic hyperplasia. J Urol. 2011;185(1):126–131. PMID: 21074209